Efficient Allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  de Yñigo Mojado, Laura ^a   Martín Ruíz, Itziar ^a   Sutherland, James D ^a  

^a CIC BIOGUNE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; LEUCINE RICH REPEAT KINASE 2; MESSENGER RNA; SHORT HAIRPIN RNA;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SPECIFICITY; EMBRYO; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; MUTANT; NUCLEOTIDE SEQUENCE; RNA INTERFERENCE; WILD TYPE;

ALLELES; BASE SEQUENCE; GENES, REPORTER; GENETIC THERAPY; HEK293 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEIC ACID CONFORMATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 79959330427     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021352     Document Type: Article

References (76)

1. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 595-600.
2. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601-607.
3. Paisan-Ruiz C, (2009) LRRK2 gene variation and its contribution to Parkinson disease. Hum Mutat 30: 1153-1160.
4. Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C, (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 31: 763-780.
5. Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, et al. (2005) Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A 102: 18676-18681.
6. Venderova K, Kabbach G, Abdel-Messih E, Zhang Y, Parks RJ, et al. (2009) Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Hum Mol Genet 18: 4390-4404.
7. Qing H, Zhang Y, Deng Y, McGeer EG, McGeer PL, (2009) Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. Biochem Biophys Res Commun 390: 1229-1234.
8. Lin X, Parisiadou L, Gu XL, Wang L, Shim H, et al. (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 64: 807-827.
9. Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, et al. (2006) Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet 14: 322-331.
10. Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, et al. (2005) Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6: 171-177.
11. Zabetian CP, Samii A, Mosley AD, Roberts JW, Leis BC, et al. (2005) A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65: 741-744.
12. West AB, Moore DJ, Choi C, Andrabi SA, Li X, et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16: 223-232.
13. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, et al. (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 357: 668-671.
14. Weiss B, (2008) ROCO kinase activity is controlled by internal GTPase function. Sci Signal 1: pe27.
15. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, et al. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9: 1231-1233.
16. Deng J, Lewis PA, Greggio E, Sluch E, Beilina A, et al. (2008) Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A 105: 1499-1504.
17. Klein CL, Rovelli G, Springer W, Schall C, Gasser T, et al. (2009) Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. J Neurochem 111: 703-715.
18. Li Y, Dunn L, Greggio E, Krumm B, Jackson GS, et al. (2009) The R1441C mutation alters the folding properties of the ROC domain of LRRK2. Biochim Biophys Acta 1792: 1194-1197.
19. Sen S, Webber PJ, West AB, (2009) Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J Biol Chem 284: 36346-36356.
20. Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, et al. (2008) The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 283: 16906-16914.
21. Greggio E, Taymans JM, Zhen EY, Ryder J, Vancraenenbroeck R, et al. (2009) The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem Biophys Res Commun 389: 449-454.
22. Kamikawaji S, Ito G, Iwatsubo T, (2009) Identification of the autophosphorylation sites of LRRK2. Biochemistry 48: 10963-10975.
23. Li X, Moore DJ, Xiong Y, Dawson TM, Dawson VL, (2010) Reevaluation of phosphorylation sites in the Parkinson's disease associated leucine rich repeat kinase-2. J Biol Chem.
24. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, et al. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405: 307-317.
25. Parisiadou L, Xie C, Cho HJ, Lin X, Gu XL, et al. (2009) Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 29: 13971-13980.
26. Covy JP, Giasson BI, (2009) Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochem Biophys Res Commun 378: 473-477.
27. Nichols RJ, Dzamko N, Hutti JE, Cantley LC, Deak M, et al. (2009) Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J 424: 47-60.
28. Boudreau RL, Davidson BL, (2006) RNAi therapy for neurodegenerative diseases. Curr Top Dev Biol 75: 73-92.
29. Kim DH, Rossi JJ, (2007) Strategies for silencing human disease using RNA interference. Nat Rev Genet 8: 173-184.
30. Lingor P, Bahr M, (2007) Targeting neurological disease with RNAi. Mol Biosyst 3: 773-780.
31. Tiemann K, Rossi JJ, (2009) RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med 1: 142-151.
32. Akaneya Y, (2010) A new approach for therapeutic use by RNA interference in the brain. Methods Mol Biol 623: 313-324.
33. Tomari Y, Zamore PD, (2005) Perspective: machines for RNAi. Genes Dev 19: 517-529.
34. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, et al. (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10: 816-820.
35. Kubodera T, Yokota T, Ishikawa K, Mizusawa H, (2005) New RNAi strategy for selective suppression of a mutant allele in polyglutamine disease. Oligonucleotides 15: 298-302.
36. Alves S, Nascimento-Ferreira I, Auregan G, Hassig R, Dufour N, et al. (2008) Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One 3: e3341.
37. Scholefield J, Greenberg LJ, Weinberg MS, Arbuthnot PB, Abdelgany A, et al. (2009) Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype. PLoS One 4: e7232.
38. Sapru MK, Yates JW, Hogan S, Jiang L, Halter J, et al. (2006) Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol 198: 382-390.
39. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, et al. (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A 102: 5820-5825.
40. Schwarz DS, Ding H, Kennington L, Moore JT, Schelter J, et al. (2006) Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2: e140.
41. Franich NR, Fitzsimons HL, Fong DM, Klugmann M, During MJ, et al. (2008) AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol Ther 16: 947-956.
42. Pfister EL, Kennington L, Straubhaar J, Wagh S, Liu W, et al. (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 19: 774-778.
43. Xia XG, Zhou H, Zhou S, Yu Y, Wu R, et al. (2005) An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase. J Neurochem 92: 362-367.
44. Raoul C, Abbas-Terki T, Bensadoun JC, Guillot S, Haase G, et al. (2005) Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 11: 423-428.
45. Ralph GS, Radcliffe PA, Day DM, Carthy JM, Leroux MA, et al. (2005) Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 11: 429-433.
46. Xia X, Zhou H, Huang Y, Xu Z, (2006) Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol Dis 23: 578-586.
47. Kubodera T, Yamada H, Anzai M, Ohira S, Yokota S, et al. (2010) In Vivo Application of an RNAi Strategy for the Selective Suppression of a Mutant Allele. Hum Gene Ther.
48. Silva JM, Li MZ, Chang K, Ge W, Golding MC, et al. (2005) Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 37: 1281-1288.
49. Westerlund M, Belin AC, Anvret A, Bickford P, Olson L, et al. (2008) Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson's disease. Neuroscience 152: 429-436.
50. Zechel S, Meinhardt A, Unsicker K, von Bohlen Und Halbach O, (2010) Expression of leucine-rich-repeat-kinase 2 (LRRK2) during embryonic development. Int J Dev Neurosci 28: 391-399.
51. Greggio E, Cookson MR, (2009) Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 1.
52. Ito G, Okai T, Fujino G, Takeda K, Ichijo H, et al. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46: 1380-1388.
53. Guo L, Gandhi PN, Wang W, Petersen RB, Wilson-Delfosse AL, et al. (2007) The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res 313: 3658-3670.
54. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, et al. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102: 16842-16847.
55. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23: 329-341.
56. Hsu CH, Chan D, Greggio E, Saha S, Guillily MD, et al. (2010) MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J Neurochem 112: 1593-1604.
57. Nichols J, Dzamko N, Morrice NA, Campbell DG, Deak M, et al. (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease associated mutations and regulates cytoplasmic localisation. Biochem J.
58. Miller VM, Xia H, Marrs GL, Gouvion CM, Lee G, et al. (2003) Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A 100: 7195-7200.
59. Miller VM, Gouvion CM, Davidson BL, Paulson HL, (2004) Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res 32: 661-668.
60. Feng X, Zhao P, He Y, Zuo Z, (2006) Allele-specific silencing of Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or London mutations. Gene 371: 68-74.
61. Rodriguez-Lebron E, Gouvion CM, Moore SA, Davidson BL, Paulson HL, (2009) Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease. Mol Ther 17: 1563-1573.
62. Ohnishi Y, Tokunaga K, Kaneko K, Hohjoh H, (2006) Assessment of allele-specific gene silencing by RNA interference with mutant and wild-type reporter alleles. J RNAi Gene Silencing 2: 154-160.
63. Ohnishi Y, Tamura Y, Yoshida M, Tokunaga K, Hohjoh H, (2008) Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi. PLoS One 3: e2248.
64. Wang YL, Liu W, Wada E, Murata M, Wada K, et al. (2005) Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci Res 53: 241-249.
65. van Bilsen PH, Jaspers L, Lombardi MS, Odekerken JC, Burright EN, et al. (2008) Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum Gene Ther 19: 710-719.
66. Lombardi MS, Jaspers L, Spronkmans C, Gellera C, Taroni F, et al. (2009) A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurol 217: 312-319.
67. Ding H, Schwarz DS, Keene A, Affar el B, Fenton L, et al. (2003) Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell 2: 209-217.
68. Towne C, Raoul C, Schneider BL, Aebischer P, (2008) Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther 16: 1018-1025.
69. Towne C, Aebischer P, (2009) Lentiviral and adeno-associated vector-based therapy for motor neuron disease through RNAi. Methods Mol Biol 555: 87-108.
70. Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, et al. (2009) Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 17: 1053-1063.
71. Andres-Mateos E, Mejias R, Sasaki M, Li X, Lin BM, et al. (2009) Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). J Neurosci 29: 15846-15850.
72. Tong Y, Yamaguchi H, Giaime E, Boyle S, Kopan R, et al. (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 107: 9879-9884.
73. Li Y, Liu W, Oo TF, Wang L, Tang Y, et al. (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 12: 826-828.
74. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, et al. (2008) Disease-specific induced pluripotent stem cells. Cell 134: 877-886.
75. Ishihara L, Warren L, Gibson R, Amouri R, Lesage S, et al. (2006) Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch Neurol 63: 1250-1254.
76. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, et al. (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 33: 401-406.